Needham upgrades Boston Scientific on selloff, cardiologist survey

Needham upgraded Boston Scientific (BSX) to Buy from Hold with a $113 price target Needham’s latest electrophysiologist survey shows the threat of pulsed field ablation competition appears less severe than previously anticipated, the analyst tells investors in a research note. The firm also sees potential for nearer-term upside for Watchman sales from concomitant use and longer-term upside from Boston Scientific’s CHAMPION trial. Additionally, the company’s two recent acquisitions of Bolt Medical and SoniVie represent new growth drivers in 2025 and beyond, contends Needham. It believes Boston Scientific shares are now more reasonably valued following the recent pullback.